The FDA approved a 21-valent pneumococcal conjugate vaccine (Capvaxive) for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults, Merck announced on Monday. Specifically ...
Please provide your email address to receive an email when new articles are posted on . Researchers compared the 21-valent vaccine to a combination of a 15-valent and 23-valent vaccines. Fewer adverse ...
Pneumococcal vaccines, like PCV13 and PPSV23, protect against serious infections caused by Streptococcus pneumoniae bacteria, which can affect children, older adults, and those with chronic health ...
Streptococcus pneumoniae is the chief cause of pneumonia in older adults, but it remains unclear whether use of the pneumococcal polysaccharide vaccine alters the overall risk of community-acquired ...
Epidemiologist; Senior Research Fellow, National Centre for Immunisation Research and Surveillance; Conjoint Senior Lecturer, Faculty of Medicine, University of Sydney; NHMRC Emerging Leadership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results